Analysts think NEO stock price could increase by 23%
Dec 24, 2024, 12:25 PM
-12.28%
What does NEO do
NeoGenomics, a clinical laboratory company based in Fort Myers, Florida, specializes in cancer genetics diagnostic testing and pharma services, employing 2,100 staff since its IPO in December 2012. Its services include clinical cancer testing and advanced diagnostics for healthcare providers and pharmaceutical companies.
14 analysts think NEO stock price will increase by 23.41%. The current median analyst target is $20.40 compared to a current stock price of $16.53. The lowest analysts target is $16.16 and the highest analyst target is $31.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
